Skip to main navigation Skip to search Skip to main content

Quality assurance of spirometry in a population-based study-predictors of good outcome in spirometry testing

  • Wan C. Tan
  • , Jean Bourbeau
  • , Denis O'donnell
  • , Shawn Aaron
  • , Francois Maltais
  • , Darcy Marciniuk
  • , Paul Hernandez
  • , Robert Cowie
  • , Kenneth Chapman
  • , A. Sonia Buist
  • , Don Sin
  • , J. Mark Fitzgerald

Research output: Contribution to journalArticlepeer-review

Abstract

Background: The assurance of high-quality spirometry testing remains a challenge. Methods: Spirometry training consisted of standardized coaching followed by certification for 35 spirometry-naïve and 9 spirometry-experienced research assistants. Spirometry was performed before and after bronchodilator (BD) in random population samples of 5176 people aged 40 years and older from 9 sites in Canada. using the hand-held EasyOne spirometer (ndd Medical Technologies Inc., Andover, MA, USA). Pulmonary function quality assurance with over reading was conducted centrally in Vancouver: spirograms were reviewed and graded according to ATS/ERS standards with prompt feedback to the technician at each site. Descriptive statistics were calculated for manoeuvre acceptability and repeatability variables. A logistic regression model was constructed for the predictors of spirometry quality success. Results: 95% of test sessions achieved pre-determined quality standards for back extrapolated volume (BEV), time to peak flow (PEFT) and end of test volume (EOTV). The mean forced expiratory time (FET) was 11.2 seconds. Then, 90% and 95% of all manoeuvres had FEV1 and FVC that were repeatable within 150 ml and 200 ml respectively. Test quality was slightly better for post-BD test sessions compared with pre-BD for both groups of research assistants. Independent predictors of acceptable test quality included participant characteristics: female sex, younger age, greater BD responsiveness; but not study site or prior experience in completing spirometry by the technologist. Conclusions: Good quality spirometry tests are attainable in large multicenter epidemiological studies by trained research assistants, irrespective of their prior experience in spirometry.

Original languageEnglish (US)
Pages (from-to)143-151
Number of pages9
JournalCOPD: Journal of Chronic Obstructive Pulmonary Disease
Volume11
Issue number2
DOIs
StatePublished - Apr 2014

Funding

In the past 5 years, Dr. Darcy Marciniuk received funding support to attend a symposium from AstraZen-eca, Boehringer Ingelheim, GlaxoSmithKline, Nycomed, and Pfizer; for speaking from AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Nycomed, and Pfizer; for consulting from AstraZeneca, Canadian Agency for Drugs and Technology in Health, GlaxoSmithKline, Health Canada, Health Quality Council, Novartis, Nycomed, Pfizer, Public Health Agency of Canada, Saskatchewan Medical Association and the Saskatoon Health Region; for research (directed to the University of Saskatchewan) from AstraZeneca, Boehringer Ingelheim, Canadian Agency for Drugs and Technology in Health, Canadian Institute of Health Research, Dal-housie University, Forest Research, GlaxoSmithKline, Lung Association of Saskatchewan, McGill University, Nycomed, Saskatchewan Health Research Foundation, Saskatchewan Ministry of Health, Schering, Pfizer, and the University of Alberta; and for organizing education from the American College of Chest Physicians, Boehringer Ingelheim, Canadian Thoracic Society, Merck, Nycomed, and the University of Saskatchewan. Dr. Marciniuk is an employee of the University of Saskatchewan. Denis O’Donnell has served on advisory boards for Boehringer Ingelheim, Pfizer, GSK, Novartis, and Nycomed; has received lecture fees from Boehringer Ingelheim, Astra Zeneca, Pfizer, and GSK; and has received industry-sponsored grants from Boehringer Ingelheim, GSK, and Merck Frosst Canada and from Novartis and Pfizer. Wan C. Tan has received funding for the operations of the Canadian Obstructive Lung Disease epidemiological study from unrestricted educational grants from Glaxo-SmithKline, Pfizer, Boehringer Ingelheim, AstraZeneca.

Funders
AstraZen-eca
Canadian Agency for Drugs and Technology in Health
Lung Association of Saskatchewan
Merck Frosst Canada
Saskatchewan Medical Association
Saskatchewan Ministry of Health, Schering
Saskatoon Health Region
Pfizer
AstraZeneca
GlaxoSmithKline
Merck
Novartis
Boehringer-Ingelheim
McGill University Health Center, McGill University
University of Saskatchewan
American College of Physicians
Canadian Thoracic Society
Public Health Agency of Canada
Canadian Institutes of Health Research
Saskatchewan Health Research Foundation
University of ALberta

    Keywords

    • Community
    • Epidemiology
    • Lung function testing
    • Primary care
    • Technologist experience

    ASJC Scopus subject areas

    • Pulmonary and Respiratory Medicine

    Fingerprint

    Dive into the research topics of 'Quality assurance of spirometry in a population-based study-predictors of good outcome in spirometry testing'. Together they form a unique fingerprint.

    Cite this